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Background and Purpose  Neurolymphomatosis is a rare manifestation of hematological 
malignancy and is characterized by direct infiltration of the peripheral nervous system. The 
objective of this study was to identify the clinical and electrophysiological features of neuro-
lymphomatosis.
Methods  We retrospectively analyzed the medical records of 13 patients with neurolympho-
matosis. Seven (54%) of the patients were men, and the median age at symptom onset was 
60.0 years.
Results  The most common type of underlying malignancy was diffuse large B-cell lympho-
ma (69%). Twelve patients had painful asymmetric neuropathies. The median survival time 
after diagnosis was 7 months, and 12 patients died during the study period. Thirty-eight mo-
tor nerve conduction studies (NCSs) were performed in the affected nerves. Ten and 28 motor 
nerves were classified into the conduction-block and simple-axon-degeneration groups, re-
spectively. The median time interval between symptom onset and the NCS was significantly 
shorter in the conduction-block group than in the simple-axon-degeneration group (p=0.032). 
However, no significant differences in the motor nerve conduction velocities, terminal laten-
cies, and distal compound muscle action potential amplitudes were identified between the con-
duction-block and simple-axon-degeneration groups. The conduction-block group showed ex-
cessive temporal dispersion in only five of the ten NCSs (50%). Follow-up NCSs revealed that 
partial conduction blocks had changed into axonal degeneration patterns.
Conclusions  This is the first study to analyze the electrophysiological features of patients with 
neurolymphomatosis. Our findings showed that a partial conduction block is not rare and is an 
early nerve conduction abnormality in neurolymphomatosis.
Key Words   neurolymphomatosis, lymphoma, leukemia, nerve conduction study, 
conduction block.
Partial Conduction Block as an Early Nerve Conduction 
Finding in Neurolymphomatosis
INTRODUCTION
Neurolymphomatosis is an extranodal manifestation of hematological malignancy and is 
characterized by direct infiltration of the peripheral nervous system. Most cases of neuro-
lymphomatosis are associated with non-Hodgkin’s lymphoma, especially diffuse large B-cell 
lymphoma.1 Neurolymphomatosis is generally thought to be an extremely rare disease; how-
ever, in one autopsy series neurolymphomatosis occurred in about 40% of patients with non-
Hodgkin’s lymphoma.2 The clinical presentation of neurolymphomatosis is highly variable. 
The most common clinical feature is painful polyradiculopathy or multiple mononeuropa-
thies, followed by painless neuropathy, cranial neuropathy, and mononeuropathy. Neuro-
lymphomatosis can develop both as a recurrent disease and as the first clinical presentation of 
hematological malignancy.3,4 Additionally, hematological malignancy can be associated with 
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not only neurolymphomatosis but also other neuropathies in-
cluding paraneoplastic neuropathy, autoimmune neuropathy, 
herpes zoster neuropathy, and chemotherapy-induced poly-
neuropathy.5,6 This clinical heterogeneity can hinder and de-
lay the diagnosis of neurolymphomatosis and may lead to a 
poor prognosis.7
Nerve biopsy is the gold standard for diagnosing neuro-
lymphomatosis, but this approach inevitably results in neuro-
logical deficits. Magnetic resonance imaging (MRI) and 18F-2-
fluoro-2-deoxy-D-glucose–positron-emission tomography/
computed tomography (FDG-PET/CT) are noninvasive imag-
ing tools that can indirectly demonstrate lymphomatous infil-
tration of the peripheral nerves and play key roles in the diag-
nosis of neurolymphomatosis.1,8,9 A nerve conduction study 
(NCS) is a basic and important modality for evaluating pe-
ripheral neuropathy. NCSs usually reveal axonal degeneration 
in patients with neurolymphomatosis, but may occasionally re-
veal a partial conduction block. Such a block is a typical nerve 
conduction finding of segmental demyelination,10-12 but its 
meaning is unclear in neurolymphomatosis. 
To understand the clinical manifestations of neurolym-
phomatosis, we investigated the clinical and electrophysio-
logical features of this disease, including the characteristics 
of neurolymphomatosis-related partial conduction block.
METHODS
Subjects
We enrolled patients with neurolymphomatosis who visited 
Severance Hospital, College of Medicine, Yonsei University 
and Mokdong Hospital, College of Medicine, Ewha Womans 
University from January 2004 to May 2017. Patients with the 
following conditions were identified from medical records: 
1) pathological diagnosis of hematological malignancy, 2) clin-
ical evidence of peripheral neuropathy, and 3) abnormal en-
largement, enhancement, or FDG uptake of clinically affected 
neural structures on limb/plexus MRI and FDG-PET/CT 
scans. We then excluded patients with underlying peripheral 
neuropathies caused by diabetes mellitus, alcohol, autoim-
mune diseases, and heavy metals. Finally, 13 patients with neu-
rolymphomatosis who met the above criteria were selected, of 
whom 11 and 2 were evaluated at Severance Hospital and 
Mokdong Hospital, respectively. The present study was initi-
ated after obtaining approval from our Institutional Review 
Board (IRB number: 4-2017-0386). The need for written in-
formed consent was waived by the review board because this 
study had a retrospective design.
Clinical assessments
Clinical data were obtained retrospectively through the medi-
cal records of the patients. The following clinical information 
was collected: sex, age at symptom onset, affected nerve struc-
tures, pain, muscle weakness, sensory deficit, malignant cell 
type, and mortality. We additionally analyzed the effectiveness 
of various diagnostic modalities such as limb/plexus MRI, 
FDG-PET/CT, cerebrospinal fluid (CSF) cytology, and nerve 
biopsy. 
Nerve conduction studies
The medical records revealed that NCSs were performed in all 
but one patient (patient 9). These electrophysiological studies 
were performed using standardized techniques with two elec-
tromyography systems: Cadwell Sierra Wave (Cadwell Labora-
tories, Kennewick, WA, USA) and Medelec Synergy (Oxford 
Instruments, Surrey, UK). Skin temperature was controlled to 
within the range of 32°C to 36°C. Motor and sensory NCSs 
were performed with surface electrodes using the conventional 
technique as outlined by Oh.13 Terminal latencies, compound 
muscle action potentials (CMAPs), and motor nerve conduc-
tion velocities (NCVs) had been recorded from the median, 
ulnar, peroneal, and tibial nerves by the belly-tendon method. 
The sensory nerve action potentials and sensory NCVs had 
been recorded from the median, ulnar, and superficial pero-
neal and sural nerves. 
A partial conduction block is defined as more than 50% 
decline of the negative-peak amplitude of the CMAP between 
distal and proximal stimulations for median and ulnar nerves 
and more than 60% decline of the negative-peak amplitude 
of the CMAP for peroneal and posterior tibial nerves, based 
on an American Association of Electrodiagnostic Medicine 
(AAEM) consensus report.14 Additionally, affected nerves 
were defined as testable terminal branches of nerves with ab-
normal enlargement, enhancement, or FDG uptake on limb/
plexus MRI and FDG-PET/CT scans. We then classified the 
findings of the motor NCSs into the conduction-block and sim-
ple-axon-degeneration groups. The conduction-block group 
was defined as motor NCS findings of partial conduction 
block. The simple-axon-degeneration group was defined as 
motor NCSs that showed CMAPs <80% of the lower limit of 
normal without marked slowing of the conduction velocity 
(<60% of the normal mean) and marked prolongation of the 
distal latency (>150% of the normal mean).13
Statistical analysis
The Mann-Whitney test was used to compare the median time 
intervals between symptom onset and NCS findings in the 
conduction-block and simple-axon-degeneration groups. Dif-
ferences were considered statistically significant at p<0.05. 
Statistical analyses were performed with SPSS (version 18.0, 
SPSS Inc., Chicago, IL, USA). 
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RESUlTS
Clinical assessment and diagnostic modalities
The clinical presentations of the 13 patients with neurolym-
phomatosis are summarized in Table 1. Seven (54%) of the pa-
tients were men, and the median age at symptom onset was 
60.0 years [interquartile range (IQR)=41.0–66.0 years]. The 
median time interval between symptom onset and diagnosis 
was 65 days (IQR=26.0–102.5 days). Neurolymphomatosis 
was the first manifestation of hematological malignancy in 
four (31%) patients and the relapse of a known malignancy in 
nine (69%). The underlying malignancy was diffuse large B-
cell lymphoma in nine (69%) patients, natural-killer/T-cell 
lymphoma in two (15%), T-cell acute lymphoblastic leukemia 
in one (8%), and a not-classified lymphoma in one (8%). Six 
(46%) and six (46%) patients had brain and cranial nerve in-
volvement, respectively. Twelve (92%) patients had painful 
asymmetric neuropathies. 
All patients received systemic chemotherapy, and four pa-
tients (patients 4, 6, 7, and 13) received intrathecal injections 
of methotrexate. Radiation therapy was performed in four 
patients (patients 3, 4, 11, and 12). Intravenous immunoglob-
ulin therapy was performed in only one patient (patient 5), 
and no patient received plasmapheresis. The median surviv-
al time after diagnosis was 7 months (IQR=3.0–15.0 months), 
and 12 (92%) patients died during the study period. Patient 
12 was alive at the last follow-up (5 months after diagnosis), 
but lymphoma had spread to the right facial nerve at 4 months 
after the diagnosis of neurolymphomatosis.
Neurolymphomatosis was diagnosed in all 13 patients 
based on FDG-PET/CT scans demonstrating increased linear 
or focal FDG uptake of the affected nerves (Supplementary 
Fig. 1 in the online-only Data Supplement). Limb/plexus MRI 
was performed in 12 patients, which revealed abnormal en-
largement or enhancement in 10 (83%) patients. All patients 
had negative findings for autoimmune antibodies including 
antinuclear antibodies, anti-double-stranded DNA antibod-
ies, antineutrophil cytoplasmic antibodies, and anti-Ro and 
Table 1. Clinical features of and diagnostic modalities used in 13 patients with NL
Patient 
no.
Sex
Onset 
age, 
years
Time from NL 
onset to  
diagnosis, days
Time from NL 
onset to death, 
months
Affected neural 
structures
Pain
Primary site of 
hematological 
malignancy
Underlying malignancy
1 F 44 235 12
Right brachial plexus
Left lumbosacral plexus
+ Peripheral nerve Not classified lymphoma
2 F 52 57 59
Left brachial plexus
Left lumbosacral plexus
+ Peripheral nerve Diffuse B-cell lymphoma
3 M 65 7 7
Left trigeminal nerve
Bilateral abducens nerve
Left facial nerve
Bilateral brachial plexus
+ Cranial nerve Diffuse B-cell lymphoma
4 F 64 64 21
Left oculomotor nerve
Bilateral brachial plexus
+ Nasal cavity mass Diffuse B-cell lymphoma
5 M 63 29 17
Left oculomotor nerve
Bilateral facial nerve
Left brachial plexus
Right lumbosacral plexus
+ Peripheral nerve Diffuse B-cell lymphoma
6 M 38 11 6
Bilateral brachial plexus
Right sciatic nerve
+ Scrotal mass NK/T-cell lymphoma
7 F 36 27 18 Right brachial plexus + Blood T-cell acute lymphoblastic leukemia
8 M 67 39 3 Multiple peripheral nerves + Cervical lymph nodes Diffuse B-cell lymphoma
9 M 53 65 5 Left brachial plexus + Ileal mass Diffuse B-cell lymphoma
10 F 70 99 10
Left brachial plexus
Right femoral nerve
+ Axillary lymph nodes Diffuse B-cell lymphoma
11 M 38 29 6 Right peroneal nerve – Scrotal mass Extranodal NK/T-cell lymphoma
12 F 60 106 5*
Left brachial plexus
Right facial nerve
+ Cervical lymph nodes Diffuse large B-cell lymphoma
13 M 68 29 10 Left brachial plexus + Brain mass Diffuse large B-cell lymphoma
*Interval from NL onset to loss to follow-up.
F: female, M: male, NK: natural killer, NL: neurolymphomatosis.
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anti-La antibodies. CSF cytology was performed in eight pa-
tients, which revealed malignant cells in three (patients 1, 3, 
and 9). A nerve biopsy was performed in three patients: pa-
tients 5 and 10 exhibited axonal degeneration with malignant 
cell infiltrates, while patient 8 showed only axonal degenera-
tion (Supplementary Fig. 2 in the online-only Data Supple-
ment).
Partial conduction block in motor NCSs
The NCS findings were compatible with multiple mononeu-
ropathies in seven patients (patients 1, 2, 3, 5, 6, 8, and 10), 
with brachial plexopathies in two patients (patients 4 and 7), 
and with mononeuropathies in three patients (patients 11, 12, 
and 13). Thirty-eight motor NCSs were performed in the af-
fected nerves showing abnormal uptake on FDG-PET/CT scans 
(Supplementary Table 1 in the online-only Data Supplement). 
The results of the motor NCSs are summarized in Table 2. 
Ten (26%) motor NCSs revealed motor conduction abnor-
malities that met the criteria for a partial conduction block, 
and these patients were therefore allocated to the conduc-
tion-block group. The other 28 (74%) motor NCSs were as-
signed to the simple-axon-degradation group. The median 
time interval between symptom onset and NCSs was signifi-
cantly shorter in the conduction-block group (median=29 
days, IQR=10–68 days) than in the simple-axon-degradation 
group (median=48 days, IQR=29–107 days, p=0.032) (Fig. 
1A). However, no significant differences in the motor NCVs, 
terminal latencies, or distal CMAP amplitudes were identi-
fied between the conduction-block and simple-axon-degra-
dation groups (Supplementary Table 2 in the online-only Data 
Supplement). The conduction-block group showed excessive 
temporal dispersion in five (50%) of the ten tests (Fig. 1B and 
C). Inching studies demonstrated partial conduction blocks 
without delayed latencies at nonentrapment sites in patients 
2 and 12 (Supplementary Fig. 3 in the online-only Data Sup-
plement). 
Partial conduction blocks were found in 7 (58%) of 12 pa-
tients with neurolymphomatosis. Partial conduction blocks 
were present at the site of increasing FDG uptake on FDG-
PET/CT scans in six of these patients. The exception was pa-
Table 2. Results of motor nerve conduction studies
Affected nerves
Negative-peak amplitude, mV
Conduction velocity, m/s Terminal latency, ms
Distal Proximal
Median nerve (n=9)*
Median [interquartile range] 2.2 [1.5–4.6] 0.9 [0–2.8] 51.6 [43.0–53.8] 3.7 [3.1–4.4]
Range 0.3–11.2 0.0–4.1 36.0–53.9 3.0–4.5
NP 2 (22)
Partial conduction block 3 (33)
Reference range >6.0 >50.5 <3.0
Ulnar nerve (n=14)
Median [interquartile range] 3.8 [1.3–5.6] 0.8 [0.6–2.7] 38.8 [36.1–52.8] 2.7 [2.6–3.1]
Range 0.5–6.5 0.8–5.0 35.3–60.6 2.2–3.5
NP 2 (14)
Partial conduction block 7 (50)
Reference range >8.0 >51.1 <2.3
Peroneal nerve (n=10)
Median [interquartile range] 1.6 [0.8–4.4] 1.5 [0.6–3.8] 41.7 [38.9–42.9] 4.3 [3.2–4.9]
Range 0.6–5.5 0.5–4.6 38.2–53.1 3.0–5.4
NP 3 (30)
Partial conduction block 0 (0)
Reference range >1.5 >40.5 <3.8
Tibial nerve (n=5)
Median [interquartile range] 2.9 [2.2–2.90] 1.8 [1.3–1.8] 40.3 [40.2–40.3] 5.0 [4.5–5.6]
Range 2.2–3.9 1.3–2.2 40.2–40.4 4.5–5.6
NP 3 (60)
Partial conduction block 0 (0)
Reference range >6 >41.1 <4.0
Data are n (%) values except where indicated otherwise.
*Number of nerves.
NP: no potentials.
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tient 12, who showed a partial conduction block between the 
wrist and elbow segment, but focal FDG uptake was present 
in the upper arm on FDG-PET/CT scans (Supplementary 
Fig. 1B in the online-only Data Supplement). However, the 
patients with and without partial conduction blocks did not 
differ with regard to other clinical characteristics such as sex, 
onset age, underlying malignancy, affected neural structures, 
pain, and survival time. Two patients (patients 2 and 5) were 
initially misdiagnosed as multifocal acquired demyelinating 
sensory and motor neuropathy due to the presence of partial 
Conduction-block group                Simple-axon-degeneration group
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400
300
200
100
0
Th
e 
tim
e 
in
te
rv
al
s 
fr
om
 s
ym
pt
om
-o
ns
et
 to
 N
CS
 (d
ay
s)
A  
Wrist :
Elbow :
Axilla :
5 mV
5 ms
Wrist :
5 mV
5 ms
Axilla :
B elbow :
A elbow :
B  
C  
Fig. 1. A partial conduction block in neurolymphomatosis. A: The median time interval between symptom onset and the NCS was significantly 
shorter in the conduction-block group than in the simple-axon-degradation group. B and C: A median motor NCS of patient 2 demonstrated a 
partial conduction block with excessive temporal dispersion (B), while an ulnar motor NCS of patient 6 revealed a partial conduction block without 
dispersion (C). NCS: nerve conduction study.
Table 3. Results of follow-up NCSs
Patient 
no.
Affected nerve NCS
Interval between 
NCSs, days
CMAP amplitude, mV Conduction 
velocity, m/s
Terminal 
latency, msDistal stimulation Proximal stimulation
2     Left ulnar      Initial 5.6 0.5 53.0 3.3
     Follow-up 360 0.5 0.4 52.2 3.5
    Left peroneal      Initial 3.9 3.5 42.9 3.2
     Follow-up 360 4.4 3.8 42.1 3.8
    Left tibial      Initial NP NP NP NP
     Follow-up 360 NP NP NP NP
    Left median*      Initial 12.6 12.0 59.0 3.5
     Follow-up 360 11.2 2.8 52.0 3.5
5     Left median      Initial 2.7 NP - 4.1
     Follow-up 78 NP NP NP NP
    Left ulnar      Initial 5.1 0.6 35.9 2.7
     Follow-up 78 NP NP NP NP
    Right peroneal      Initial 5.5 4.6 53.1 3.0
     Follow-up 78 0.6 0.6 41.7 4.3
*Complained of sensory deficits and motor weakness after the follow-up NCS.
CMAP: compound muscle action potential, NCS: nerve conduction study, NP: no potentials.
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conduction blocks. Follow-up NCSs demonstrated that the 
initial partial conduction blocks had converted to axonal de-
generation (Table 3, Fig. 2). Patient 2 received systemic che-
motherapy during the interval from the first to the follow-up 
NCS, whereas patient 5 received steroid and immunoglobulin 
therapies instead of chemotherapy because he was diagnosed 
as neurolymphomatosis after the follow-up NCS.
DISCUSSION
The present study characterized the clinical manifestations, 
utility of various diagnostic modalities, and NCS findings in 
13 patients with neurolymphomatosis. Nerve pathology and 
CSF cytology demonstrated malignant cells in 2 and 3 of the 
13 patients, respectively. Nerve biopsy is not routinely per-
formed in all patients with neurolymphomatosis because the 
affected lesions are frequently located in the deep-seated plex-
us, root, or cranial nerves, and because a nerve biopsy usually 
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Fig. 2. Findings of follow-up NCSs of the affected nerves with a partial conduction block. In patient 2, the initial motor NCS of the left ulnar nerve 
demonstrated a partial conduction block (A), but the follow-up NCS performed 360 days later produced results compatible with axon degenera-
tion (B). In patient 5, conduction blocks were found during the initial motor NCS of the left median (C) and ulnar (E) nerves, while the NCS per-
formed 78 days later did not show potentials (D and F). NCS: nerve conduction study.
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results in permanent motor weakness and sensory deficits. 
Additionally, the sensitivity of CSF cytology is very low, at 20–
40%.1,15 Therefore, the other eight patients had their neurolym-
phomatosis pathologically confirmed at extraneural sites; addi-
tionally, MRI and FDG-PET/CT scans were used to identify 
the peripheral nerve infiltration that is associated with hema-
tological malignancy.
The clinical presentations of the present patients with neu-
rolymphomatosis were similar to those reported previous-
ly.1,12,15 The age at the onset of neurolymphomatosis was >50 
years in 69% of the patients. All patients except patient 11 had 
painful and asymmetrical peripheral neuropathy involving 
damage to multiple nerves. Neurolymphomatosis was the first 
manifestation of hematological malignancy in one-third of the 
patients. About half of the patients had brain or cranial nerve 
involvement. The median time interval between symptom on-
set and diagnosis was about 2 months, and it was 8 months in 
patient 1. The median survival time was 7 months after diag-
nosis, and 12 patients died. Among the diagnostic modalities 
used, FDG-PET/CT and limb/plexus MRI scans performed 
well by demonstrating abnormalities in 100% and 83% of the 
patients, respectively. On the other hand, the sensitivity of CSF 
cytology was very low (38%), which is compatible with the 
findings of previous studies.3,8,9,12,16,17 A nerve biopsy did not 
pathologically confirm lymphoma infiltration in patient 8; 
this biopsy involved the sural nerve, which is a distal sensory 
branch of the sciatic nerve, and FDG-PET/CT scans of this 
patient revealed abnormal uptake at the proximal part of the 
sciatic nerve.
Partial conduction blocks were found in 58% of the patients 
in this study. This characteristic NCS finding has been occa-
sionally reported in neurolymphomatosis.11,12,18 A partial con-
duction block generally indicates that saltatory conduction 
has stopped even though the axon remains relatively intact. 
Therefore, previous authors have suggested that partial con-
duction block is linked to the infiltration pattern of hemato-
logical malignancy or humoral factors produced by lympho-
ma.12 Indeed, hematological malignancy occasionally infiltrates 
around the nerves–and not within the nerves–in several nerve 
pathologies.12,18,19 However, the precise mechanism underlying 
a partial conduction block remains unclear.
Several aspects of our electrophysiological results suggest 
that the mechanism of partial conduction in neurolympho-
matosis is axonal degeneration. First, none of the NCS findings 
except a partial conduction block differed significantly be-
tween the conduction-block and simple-axon-degradation 
groups. Second, partial conduction blocks were identified by 
NCSs performed within 3 months after symptom onset and had 
converted into simple-axon-degeneration patterns by the time 
of the follow-up NCSs. Third, the shape and pattern of par-
tial conduction blocks in our patients with neurolymphoma-
tosis differed from those identified in patients with demyelin-
ating neuropathies. Partial conduction blocks without delayed 
latencies were found at nonentrapment sites in our neurolym-
phomatosis patients, while temporal dispersion was identified 
in only half of the patients. Finally, the nerve pathologies were 
compatible with axonal degeneration in both our own pre-
vious studies and those of others.12,18,20 However, the partial 
conduction blocks lasted for longer in neurolymphomatosis 
than in other axonal neuropathies. Partial conduction blocks 
have been reported as a transient NCS finding in the early 
phase of axonal neuropathies.21-23 
The pathophysiology of a partial conduction block in acute 
motor axonal neuropathy is assumed to be associated with 
complement deposits at the nodes of Ranvier.24 This char-
acteristic finding in vasculitic neuropathy is assumed to be 
related to metabolic block, paranodal demyelination, segmen-
tal demyelination, and Wallerian degeneration, which reflect 
different degrees of ischemic damage.22,23 Partial conduction 
blocks are usually identified less than a week after symptom 
onset,21-23 while the partial conduction blocks in the present 
study lasted for 3 months after symptom onset in neurolym-
phomatosis. We therefore assume that partial conduction in 
neurolymphomatosis might be caused by both axonal degen-
eration and segmental demyelination rather than by a single 
pathomechanism.
It is important to note that this was a small retrospective 
study and as such does not provide sufficient evidence regard-
ing the pathomechanism of a partial conduction block in pa-
tients with neurolymphomatosis. Further prospective studies 
are therefore needed to confirm our results in larger cohorts 
and to identify the pathogenic mechanisms of a partial con-
duction block in neurolymphomatosis.
Collectively, the results of the present study demonstrate 
that partial conduction blocks are a temporary NCS finding 
in about half of all patients with neurolymphomatosis. Partial 
conduction blocks frequently result in delayed diagnoses or 
misdiagnoses of neurolymphomatosis, which in turn leads to 
the spread of the malignancy and a poor prognosis. Clinicians 
therefore need to be aware that neurolymphomatosis can be 
associated with partial conduction blocks, especially in pa-
tients with painful asymmetric neuropathies or multiple mono-
neuropathies. In conclusion, the present study improves our 
understanding of the clinical and electrophysiological findings 
associated with neurolymphomatosis, and is the first study to 
identify a partial conduction block as an early nerve conduc-
tion abnormality in patients with neurolymphomatosis.
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